Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stake Lowered by Convergence Investment Partners LLC

Convergence Investment Partners LLC cut its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 20.5% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 45,441 shares of the specialty pharmaceutical company’s stock after selling 11,739 shares during the period. Convergence Investment Partners LLC owned 0.09% of Supernus Pharmaceuticals worth $1,959,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Juncture Wealth Strategies LLC boosted its stake in Supernus Pharmaceuticals by 0.8% in the first quarter. Juncture Wealth Strategies LLC now owns 51,459 shares of the specialty pharmaceutical company’s stock valued at $1,611,000 after buying an additional 433 shares during the period. Virginia Retirement Systems ET AL boosted its stake in Supernus Pharmaceuticals by 17.1% in the first quarter. Virginia Retirement Systems ET AL now owns 71,800 shares of the specialty pharmaceutical company’s stock valued at $2,247,000 after buying an additional 10,500 shares during the period. Turner Investments LLC purchased a new stake in Supernus Pharmaceuticals during the first quarter valued at approximately $219,000. Sheets Smith Wealth Management purchased a new stake in Supernus Pharmaceuticals during the second quarter valued at approximately $378,000. Finally, Bank of America Corp DE boosted its stake in Supernus Pharmaceuticals by 10.7% in the first quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock valued at $11,361,000 after buying an additional 35,069 shares during the period. Institutional investors own 92.80% of the company’s stock.

Supernus Pharmaceuticals, Inc. (SUPN) opened at 41.40 on Monday. The stock has a 50 day moving average of $42.47 and a 200-day moving average of $34.12. Supernus Pharmaceuticals, Inc. has a one year low of $17.25 and a one year high of $44.95. The stock has a market cap of $2.10 billion, a P/E ratio of 20.89 and a beta of 1.31.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million during the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. Analysts anticipate that Supernus Pharmaceuticals, Inc. will post $1.04 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.com-unik.info/2017/08/14/supernus-pharmaceuticals-inc-nasdaqsupn-stake-lowered-by-convergence-investment-partners-llc.html.

Several analysts have recently commented on SUPN shares. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 target price for the company in a research note on Thursday, July 13th. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Jefferies Group LLC set a $35.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 10th. Stifel Nicolaus restated a “buy” rating and issued a $47.00 target price (up previously from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Finally, Piper Jaffray Companies cut shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $46.00 target price for the company. in a research note on Monday, July 17th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Supernus Pharmaceuticals has an average rating of “Buy” and an average target price of $48.43.

In related news, VP Padmanabh P. Bhatt sold 10,000 shares of the company’s stock in a transaction dated Friday, June 2nd. The shares were sold at an average price of $39.86, for a total value of $398,600.00. Following the completion of the sale, the vice president now owns 27,500 shares of the company’s stock, valued at $1,096,150. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 2,500 shares of the company’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $35.90, for a total transaction of $89,750.00. Following the completion of the sale, the vice president now directly owns 37,500 shares of the company’s stock, valued at approximately $1,346,250. The disclosure for this sale can be found here. Insiders sold 24,291 shares of company stock valued at $962,766 in the last ninety days. Corporate insiders own 6.70% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit